Clinical Trials for Newly Diagnosed Myeloma Patients with John Rosengard
Clinical Trials are often considered for those at the end of their treatment who are in need of novel therapies. But is there a need for newly diagnosed patients to participate in clinical trials as well? Come hear the patient experience of myeloma patient, John Rosengard, who participated in the GRIFFIN trial when he was newly diagnosed.
Audrey Burton-Bethke
Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
John Rosengard
John Rosengard is a multiple myeloma survivor from Oakland, California. He is a patient of Dr. Nina Shah at UCSF and participated in the GRIFFIN clinical trial from 2017-2021. He works in the environmental cleanup field and worked full time through treatment…except for the weeks after the 2018 stem cell transplant! He is a MyelomaTree coach and active supporter of his fellow patients.
Todd Foster
Todd Foster is the Director of Digital Patient Engagement at HealthTree. He worked at MD Anderson Cancer Center for 12 years before helping myeloma patient, Jenny Ahlstrom, start up HealthTree. He specializes in patient experience, helping patients understand their options, and becoming decision makers with their care teams. Prior experience includes IT development projects at Intermountain HealthCare and UnitedHealthcare. Todd has a passion for using technology that can help patients have a better life, and along the way, help to further research for a cure.